转移性激素敏感性前列腺癌原发肿瘤转录组分析及与临床结局的关联:E3805 CHAARTED试验的相关性分析
该研究对CHAARTED试验中160例转移性激素敏感性前列腺癌患者的原发肿瘤组织进行全转录组分析,发现与原发局限性前列腺癌相比,转移性患者以luminal B(50%)和基底型(48%)亚型为主,且AR活性较低、Decipher高风险比例高。Luminal B亚型在单纯ADT治疗下预后较差,但接受ADT+多西他赛治疗显著获益(OS HR 0.45,P=0.007),而基底型无OS获益(HR 0.85,P=0.58)。Decipher高风险和低AR活性与更差OS显著相关,且Decipher高风险患者从ADT+多西他赛中获得更大OS改善(HR 0.41,P=0.015)。
要点
- 转移性激素敏感性前列腺癌原发肿瘤以luminal B和基底型为主,AR活性低、Decipher高风险多见。
- Luminal B亚型可从ADT+多西他赛显著获益,基底型即使高瘤负荷也无OS获益。
- Decipher高风险和低AR活性与更差OS相关,Decipher高风险者化疗联合获益更大。
核心结论
- 转录组分型可用于mHSPC预后判断及化疗联合治疗的患者选择,为生物标志物指导的联合治疗选择提供概念验证。
研究设计与样本
- 对CHAARTED试验中入组前未接受系统治疗的160例mHSPC患者原发前列腺癌组织进行全转录组分析,预设分析方案检验RNA特征与临床表型及结局的关联,多变量分析校正年龄、ECOG评分、新发转移、瘤负荷和治疗臂。
主要发现
- 与原发局限性前列腺癌相比,mHSPC原发肿瘤转录谱差异显著,以luminal B(50%)和基底型(48%)亚型为主,AR活性较低,Decipher高风险疾病比例高。
- Luminal B亚型在单纯ADT治疗下预后较差,但接受ADT+多西他赛治疗显著获益(OS HR 0.45;P=0.007)。
- 基底型亚型未显示OS获益(HR 0.85;P=0.58),即使在高瘤负荷患者中亦然。
- 多变量分析中,较高的Decipher风险和较低的AR活性与更差OS显著相关。
- 较高的Decipher风险患者接受ADT+多西他赛治疗显示更大的OS改善(HR 0.41;P=0.015)。
临床怎么用
- 可考虑对mHSPC原发肿瘤进行转录组分型(如luminal B vs 基底型)及Decipher风险评分,以辅助预后判断和化疗联合治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase III CHAARTED trial established upfront androgen-deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate cancer (mHSPC) based on meaningful improvement in overall survival (OS). Biological prognostic markers of outcomes and predictors of chemotherapy benefit are undefined. PATIENTS AND METHODS: Whole transcriptomic profiling was performed on primary PC tissue obtained from patients enrolled in CHAARTED prior to systemic therapy. We adopted an a priori analytical plan to test defined RNA signatures and their associations with HSPC clinical phenotypes and outcomes. Multivariable analyses (MVAs) were adjusted for age, Eastern Cooperative Oncology Group status, de novo metastasis presentation, volume of disease, and treatment arm. The primary endpoint was OS; the secondary endpoint was time to castration-resistant PC. RESULTS: The analytic cohort of 160 patients demonstrated marked differences in transcriptional profile compared with localized PC, with a predominance of luminal B (50%) and basal (48%) subtypes, lower androgen receptor activity (AR-A), and high Decipher risk disease. Luminal B subtype was associated with poorer prognosis on ADT alone but benefited significantly from ADT + D [OS: hazard ratio (HR) 0.45; P = 0.007], in contrast to basal subtype which showed no OS benefit (HR 0.85; P = 0.58), even in those with high-volume disease. Higher Decipher risk and lower AR-A were significantly associated with poorer OS in MVA. In addition, higher Decipher risk showed greater improvements in OS with ADT + D (HR 0.41; P = 0.015). CONCLUSION: This study demonstrates the utility of transcriptomic subtyping to guide prognostication in mHSPC and potential selection of patients for chemohormonal therapy, and provides proof of concept for the possibility of biomarker-guided selection of established combination therapies in mHSPC.
引用
- Hamid AA, Huang HC, Wang V, et al. Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. Ann Oncol. 2021. PMID: 34129855. doi:10.1016/j.annonc.2021.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。